Cinacalcet Cost-Effective When “Stopping Rules” Are Applied, Amgen Contends
This article was originally published in The Pink Sheet Daily
Executive Summary
NICE draft appraisal concludes hyperparathyroidism therapy is unlikely to be considered cost-effective.
You may also be interested in...
Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation
NICE determination limits recommended use to severe refractory SHPT patients.
Amgen Satisfied With Mixed Cinacalcet Cost-Effectiveness Recommendation
NICE determination limits recommended use to severe refractory SHPT patients.
Amgen Sensipar Approved; Target U.S. Market At Least 300,000 Patients
Cinacalcet is indicated for the treatment of hyperparathyroidism associated with kidney disease and hypercalcemia in parathyroid cancer patients.